Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection

被引:75
作者
Kovari, Helen [1 ]
Ledergerber, Bruno [1 ]
Battegay, Manuel [2 ]
Rauch, Andri [3 ,4 ]
Hirschel, Bernard [5 ]
Foguena, Alain Kenfak [6 ]
Vernazza, Pietro [7 ]
Bernasconi, Enos [8 ]
Mueller, Nicolas J. [1 ]
Weber, Rainer [1 ]
机构
[1] Univ Zurich, Univ Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland
[2] Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland
[3] Univ Hosp Bern, Univ Clin Infect Dis, CH-3010 Bern, Switzerland
[4] Univ Bern, Bern, Switzerland
[5] Univ Hosp, Div Infect Dis, Geneva, Switzerland
[6] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland
[7] Cantonal Hosp, Div Infect Dis, St Gallen, Switzerland
[8] Osped Reg, Lugano, Switzerland
基金
瑞士国家科学基金会;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; FATTY LIVER-DISEASE; ANTIRETROVIRAL THERAPY; UNITED-STATES; STEATOSIS; PREVALENCE; HEPATOTOXICITY; NUCLEOSIDE; MORTALITY; TOXICITY;
D O I
10.1086/649922
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Chronic liver disease in human immunodeficiency virus (HIV)-infected patients is mostly caused by hepatitis virus co-infection. Other reasons for chronic alanine aminotransferase (ALT) elevation are more difficult to diagnose. Methods. We studied the incidence of and risk factors for chronic elevation of ALT levels (greater than the upper limit of normal at >= 2 consecutive semi-annual visits) in participants of the Swiss HIV Cohort Study without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection who were seen during the period 2002-2008. Poisson regression analysis was used. Results. A total of 2365 participants were followed up for 9972 person-years (median age, 38 years; male sex, 66%; median CD4(+) cell count, 426/mu L; receipt of antiretroviral therapy [ART], 56%). A total of 385 participants (16%) developed chronic elevated ALT levels, with an incidence of 3.9 cases per 100 person-years (95% confidence interval [CI], 3.5-4.3 cases per 100 person-years). In multivariable analysis, chronic elevated ALT levels were associated with HIV RNA level >100,000 copies/mL (incidence rate ratio [IRR], 2.23; 95% CI, 1.45-3.43), increased body mass index (BMI, defined as weight in kilograms divided by the square of height in meters) (BMI of 2529.9 was associated with an IRR of 1.56 [95% CI, 1.24-1.96]; a BMI >= 30 was associated with an IRR of 1.70 [95% CI, 1.16-2.51]), severe alcohol use (1.83 [1.19-2.80]), exposure to stavudine (IRR per year exposure, 1.12 [95% CI, 1.07-1.17]) and zidovudine (IRR per years of exposure, 1.04 [95% CI, 1.00-1.08]). Associations with cumulative exposure to combination ART, nucleoside reverse-transcriptase inhibitors, and unboosted protease inhibitors did not remain statistically significant after adjustment for exposure to stavudine. Black ethnicity was inversely correlated (IRR, 0.52 [95% CI, 0.33-0.82]). Treatment outcome and mortality did not differ between groups with and groups without elevated ALT levels. Conclusions. Among patients without hepatitis virus co-infection, the incidence of chronic elevated ALT levels was 3.9 cases per 100 person-years, which was associated with high HIV RNA levels, increased BMI, severe alcohol use, and prolonged stavudine and zidovudine exposure. Long-term follow-up is needed to assess whether chronic elevation of ALT levels will result in increased morbidity or mortality.
引用
收藏
页码:502 / 511
页数:10
相关论文
共 37 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]  
[Anonymous], 2002, Gastroenterology, V123, P1702
[3]   Liver toxicity in epidemiological cohorts [J].
Becker, S .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S49-S55
[4]   HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? [J].
Blackard, J. T. ;
Sherman, K. E. .
JOURNAL OF VIRAL HEPATITIS, 2008, 15 (05) :323-330
[5]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[6]   Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons [J].
Crum-Cianflone, Nancy ;
Dilay, Angelica ;
Collins, Gary ;
Asher, Dean ;
Campin, Richard ;
Medina, Sheila ;
Goodman, Zach ;
Parker, Robin ;
Lifson, Alan ;
Capozza, Thomas ;
Bavaro, Mary ;
Hale, Braden ;
Hames, Charles .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (05) :464-473
[7]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[8]  
FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
[9]   Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: Impact of hepatitis C coinfection [J].
French, AL ;
Benning, L ;
Anastos, K ;
Augenbraun, M ;
Nowicki, M ;
Sathasivam, K ;
Terrault, NA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) :402-410
[10]  
Genuth S, 2003, DIABETES CARE, V26, P3160